Cocrystal Pharma Inc (COCP)
$2.04
Live
Performance
- $2.04$2.11$2.04
0.0%
Downside
Day's Volatility :3.09%
Upside
3.09%
- $1.33$3.10$2.04
35.05%
Downside
52 Weeks Volatility :57.26%
Upside
34.19%
Returns
| Period | Cocrystal Pharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -11.46% | 0.0% |
6 Months | 36.3% | 0.0% |
1 Year | 27.89% | 0.0% |
3 Years | -82.22% | -23.0% |
Highlights
Market Capitalization | 20.8M |
Book Value | $1.71 |
Earnings Per Share (EPS) | -1.75 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -46.06% |
Return On Equity TTM | -68.86% |
Revenue TTM | 510.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 26.900000000000002% |
Gross Profit TTM | -8.8M |
EBITDA | -21.2M |
Diluted Eps TTM | -1.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.94 |
EPS Estimate Next Year | -2.21 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.5 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 292.16%
Technicals Summary
Sell
Neutral
Buy
Cocrystal Pharma Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cocrystal Pharma Inc | 15.74% | 36.3% | 27.89% | -82.22% | -83.71% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cocrystal Pharma Inc | NA | NA | 0.0 | -1.94 | -0.69 | -0.46 | NA | 1.71 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cocrystal Pharma Inc | Buy | $20.8M | -83.71% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Cocrystal Pharma Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 61.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 127.0%
Institutional Holdings
Vanguard Group Inc
2.71%Renaissance Technologies Corp
1.28%BlackRock Inc
0.72%Geode Capital Management, LLC
0.64%Morgan Stanley - Brokerage Accounts
0.58%Susquehanna International Group, LLP
0.25%
Company Information
cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.
Organization | Cocrystal Pharma Inc |
Employees | 12 |
CEO | Dr. Sam Lee Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.04
-1.54%
Invesco Bulletshares 2025 Hi
$2.04
-1.54%
Schwab International Dividend Equity Etf
$2.04
-1.54%
Blockchain Coinvestors Acquisition Corp.
$2.04
-1.54%
Allgiant Travel Company
$2.04
-1.54%
Rogers Corp
$2.04
-1.54%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.04
-1.54%
Iheartmedia
$2.04
-1.54%
Lightpath Technologies Inc
$2.04
-1.54%